mRNA-1273 continues to be efficacious at five months
Sep 27, 2021
The efficacy of mRNA-1273, the Moderna vaccine, was 93.2% for preventing COVID-19 illness and 98.2% for preventing severe COVID-19.
Protection against omicron strongest with hybrid immunity
Jun 17, 2022
Immunity resulting from previous COVID-19 infection and recent booster vaccination confers the strongest protection against the omicron infection.
Overall risk of myopericarditis low after COVID-19 vaccine
Apr 12, 2022
The overall incidence of myopericarditis does not differ significantly for those receiving COVID-19 vaccines versus non-COVID-19 vaccines.
Racial/ethnic disparities persist in adult vaccination coverage
Jul 29, 2021
Racial and ethnic disparities in vaccine coverage persisted over the last decade among adults aged 65 years and older, according to a study published online July 29 in the American Journal of Preventive...
Homologous, heterologous COVID-19 boosters are immunogenic
Feb 07, 2022
Antibody neutralizing titers against SARS-CoV-2 D614G pseudovirus increased by a factor of 4 to 73 for all combinations.
Adverse events associated with BNT162b2 vaccination ID’d
Aug 27, 2021
Vaccination with the Pfizer–BioNTech mRNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with an increased risk for myocarditis and lymphadenopathy, according...
Protection against SARS-CoV-2 wanes months after BNT162b2 vaccination
Oct 08, 2021
Declines were seen in humoral responses and effectiveness against SARS-CoV-2 infection within several months after the second dose of the Pfizer-BioNTech vaccine, also known as Comirnaty.
Vaccines effective in preventing symptomatic COVID-19 in healthcare workers
Sep 27, 2021
Effectiveness was similar regardless of age (
COVID-19 vaccination tied to decline in distress in U.S. adults
Feb 24, 2022
Decreases in distress and perceived risks for infection, hospitalization and death were reported by those receiving at least one dose of the vaccine.
SARS-CoV-2 vaccines effectively prevent infection in VA population
Jul 20, 2021
Vaccine effectiveness was 96.2% for Pfizer-BioNTech BNT162b2 and 98.2% for Moderna mRNA-1273.